Glycochenodeoxycholic Acid (GCDCA): A Comprehensive Reference
1. Identity and Chemical Characterization
Names and Synonyms
Glycochenodeoxycholic acid (GCDCA) carries the CAS number 640-79-9 and is known under several synonyms including Glycochenodeoxycholate, GCDC, Chenodeoxycholylglycine, Glycinodeoxycholic acid, Glycine chenodeoxycholate, and Glycoanthropodeoxycholic acid. Its molecular formula is C26H43NO5 and its molecular weight is 449.62 Da. By IUPAC/ChEBI definition, GCDCA is a bile acid glycine conjugate having 3α,7α-dihydroxy-5β-cholan-24-oyl as the bile acid component.
Structural Features
Bile salts such as GCDCA contain a steroid core structure composed of a large family of molecules including four fused rings, with the steroid core containing three cyclohexane rings (the A, B, and C rings) and one cyclopentane ring (the D ring), a conserved feature across all bile salt species. The bile acid structure is comprised of three six-carbon rings (a, b, and c) and a five-carbon ring (d), with a flat geometry depending on the cis- or trans- conformation between the first two rings; the concave face is hydrophilic due to hydroxyl groups, while the convex side is hydrophobic due to methyl groups. In GCDCA specifically, two hydroxyl groups are positioned at the 3α and 7α positions of the steroid nucleus, with the C-24 carboxyl group conjugated to the amino acid glycine via an amide bond.
Classification within Bile Acids
Bile acids, also known as steroid acids, are amphiphilic water-soluble molecules that are mainly synthesized by the liver (primary forms) and through bacterial transformation in the colon (secondary forms). Primary bile acids are those synthesized by the liver; secondary bile acids result from bacterial actions in the colon. In humans, taurocholic acid and glycocholic acid (derivatives of cholic acid) and taurochenodeoxycholic acid and glycochenodeoxycholic acid (derivatives of chenodeoxycholic acid) are the major bile salts. The salts of their 7-alpha-dehydroxylated derivatives, deoxycholic acid and lithocholic acid, are also found, with derivatives of cholic, chenodeoxycholic and deoxycholic acids accounting for over 90% of human biliary bile acids; bile acids comprise about 80% of the organic compounds in bile.
2. Natural Sources and Biosynthesis
Endogenous Hepatic Synthesis
Glycochenodeoxycholic acid is a bile salt formed in the liver from chenodeoxycholic acid and glycine, usually found as the sodium salt. Free primary bile acids such as cholic acid (CA) and chenodeoxycholic acid (CDCA) are created from cholesterol in hepatocytes and quickly conjugated via bile acid cholyl-CoA synthetase to generate taurine- or glycine-conjugated bile acids, including glycochenodeoxycholic acid (GCDCA). In humans, bile acids are conjugated in the liver with glycine (G) or taurine (T) to form tauro-CA (TCA), tauro-CDCA (TCDCA), glyco-CA (GCA) and glycol-CDCA (GCDCA), whereas mice use almost exclusively taurine.
Primary bile acids are synthesized from cholesterol in hepatocytes by cholesterol 7α-hydroxylase (CYP7A1) and released into the intestinal tract with the bile; approximately 95% of bile acids in the intestine are reabsorbed and transported back to the liver via the portal vein, while the remainder escapes enterohepatic circulation and enters the colon, where intestinal bacteria transform them through 7α-dehydroxylation into secondary bile acids.
Animal Sources
Different animal biles can be distinguished by their major characteristic bile acids: tauroursodeoxycholic acid and taurochenodeoxycholic acid for bear bile, glycocholic acid, cholic acid and taurocholic acid for cattle bile, glycohyodeoxycholic acid and glycochenodeoxycholic acid for pig bile, and taurocholic acid for snake bile. Thus, pig bile is a particularly rich natural exogenous source of GCDCA among traditional animal-derived preparations.
Storage and Secretion
These bile acids are actively secreted from the liver across the canalicular transporters of hepatocytes into the bile canaliculi and stored in the gallbladder. Upon food intake, the duodenum releases secretin that stimulates biliary duct cells to produce bicarbonate and water to increase bile volume, and cholecystokinin that stimulates gallbladder contraction, causing bile moieties to be released into the duodenum. In humans, CDCA is predominantly conjugated with glycine to form GCDCA and rarely with taurine to form TCDCA; the introduction of glycine increases amphiphilicity and optimizes the spatial conformation of the molecule, making it easier to interact with the cell membrane.
3. Traditional and Historical Use
Traditional Chinese Medicine
With a history of more than 1,000 years in China, bile has long been an essential component of animal medicines in traditional Chinese medicine (TCM); cattle bile powder — a dried product of bile — appeared as green-brown or brownish chunks or powder, among other preparations. For centuries, dried ox or bear bile, which naturally contains glycochenodeoxycholic acid and related compounds, was a valued ingredient in Chinese and other Asian medicinal systems, with these remedies believed to promote liver health and support digestion.
Bear bile has been used in Traditional Chinese Medicine (TCM) for thousands of years; modern investigations show that it has a wide range of pharmacological actions with little toxicological side effect, and the pure compounds have been used for curing hepatic and biliary disorders for decades. For thousands of years, bear bile was used in traditional Chinese medicine as a cure for liver and gallbladder disease; TCM practitioners maintain that the cool, bitter flavor of bear bile diffuses a "heat" concentrated in the liver, restoring bodily harmony.
The direct use of GCDCA as an isolated compound in traditional medicine is limited; rather, its parent molecules — bile acids — have a rich history of medicinal applications, particularly in Eastern and traditional remedies. Historically, bile extracts were also incorporated into herbal combinations to enhance their efficacy in treating digestive complaints — for example, they were often blended with botanical ingredients like rhubarb or scutellaria root to relieve indigestion, support detoxification, and reduce inflammation.
GCDCA itself is not a traditional medicine monograph substance. It was identified as a discrete chemical entity during the systematic study of bile acid chemistry in the 19th and 20th centuries, following the original isolation of its parent compound, chenodeoxycholic acid. Chenodeoxycholic acid — 3α,7α-dihydroxy-5β-cholan-24-oic acid — was first isolated from the domestic goose, from which the "cheno" prefix of the name was derived (Greek: χήν = goose).
4. Key Constituents, Active Compounds, and Mechanisms of Action
Physicochemical Properties and Surfactant Action
GCDCA acts as a detergent to solubilize fats for absorption. As a bile acid, GCDCA functions to solubilize lipids for digestive absorption; by acting as a biosurfactant, it can solubilize lipids for absorption and is itself absorbed. GCDCA may also inhibit calcium phosphate precipitation by preventing the formation of amorphous calcium phosphate to calcium hydroxyapatite.
Receptor Signaling: FXR and TGR5
Postprandial signaling by bile acids is considered to be mainly mediated via activation of the bile acid receptors Takeda G protein-coupled receptor 5 (TGR5) and Farnesoid X receptor (FXR). Regarding GCDCA's specific receptor preference, research indicates a nuanced picture. Upon evaluating the transcriptional activity of FXR using a luciferase reporter system in HEK293T cells, GCDCA stimulation had no significant effect on FXR luciferase activity; by contrast, HTLA cells transfected with the S1PR2-Tango plasmid showed significantly enhanced fluorescence intensity after GCDCA stimulation, suggesting that GCDCA exerts its biological effects by activating the S1PR2 (sphingosine-1-phosphate receptor 2) receptor rather than the FXR receptor.
Evidence suggests that TGR5 preferentially binds to primary bile acids compared with FXR; accordingly, CDCA and GCDCA may exert their effects through a mechanism more closely aligned with TGR5 activation than FXR activation. The receptor context is also cell-type and condition dependent.
Pro-Apoptotic Mechanisms in Hepatocytes
GCDCA-induced hepatocellular death was first established as apoptotic using electron microscopy; incubation of primary rat hepatocytes with 50 μmol/L GCDCA induced DNA fragmentation, chromatin margination and condensation, cellular shrinkage and blebbing of the membrane with intact organelles. While DNA fragmentation is common to both necrosis and apoptosis, the morphological changes present after GCDCA exposure provided strong evidence of bile acid-induced apoptosis of primary hepatocytes; in immortalized cell lines transfected with the basolateral transporter NTCP, GCDCA could directly stimulate both Fas-dependent apoptosis via activation of the Fas receptor and Fas-independent apoptosis via previously established mitochondrial damaging mechanisms.
Studies on rats have shown that GCDCA-induced hepatocyte apoptosis is related to the early regulation of intracellular protein kinase C (PKC) signaling pathway, a pathway regulating many key liver functions. GCDCA also negatively regulates the expression of transcription factor E3 (TFE3) and suppresses the formation of autophagosomes and impairs lysosomal function, resulting in damaged autophagic flux in LO2 cells.
Endogenous Mfn2 (Mitofusin 2) expression is decreased in patients with extrahepatic cholestasis; GCDCA is the main toxic component of bile acid in patients with extrahepatic cholestasis, and in human normal hepatocyte cells (L02), Mfn2 plays an important role in GCDCA-induced mitochondrial damage and changes in mitochondrial morphology.
Transport: OATP Transporters
The uptake of individual bile acids has been compared in HEK293 cells over-expressing either human OATP1B1 or OATP1B3; conjugated bile acids were found to be the preferred substrates for these two transporters, with significant transport of many unconjugated bile acids not demonstrable. The 3-sulfate conjugate of glycochenodeoxycholate and the 24-glucuronide conjugate of chenodeoxycholic acid were found to be substrates of OATP1B1 and OATP1B3.
Autocrine Inflammation Modulation
Previous studies have reported that GCDCA treatment suppresses the release of IL-6 and TNF-α through the TGR5 receptor in THP-1 cells infected with SFTSV (Severe Fever with Thrombocytopenia Syndrome Virus). Data have supported anti-inflammatory effects of CDCA, GCDCA, FXR activation, and TGR5 activation in THP-1 cells stimulated by SARS-CoV-2; GCDCA exhibited a more evident inhibitory effect on the inflammation response than CDCA.
5. Body Systems and Health Areas
Digestive System: Fat Absorption and Lipid Emulsification
Traditionally, GCDCA and related bile acids have played a critical role in the emulsification and absorption of dietary fats and fat-soluble vitamins, underpinning their longstanding significance in human nutrition and metabolism. GCDCA's amphiphilic structure enables it to form mixed micelles with dietary lipids and phospholipids in the small intestinal lumen, presenting lipid substrates to absorptive epithelial enzymes and facilitating uptake of fat-soluble vitamins A, D, E, and K.
Hepatobiliary System: Cholestasis and Liver Injury
GCDCA is a toxic component of bile acid that is found in patients with extrahepatic cholestasis; it is a pro-apoptotic bile acid that directly causes apoptosis in vitro in hepatocytes by ligand-independent activation of Fas and probably TRAIL receptor 2/DR5. The common consequence of all forms of cholestasis is retention of bile acids and other potentially toxic compounds in hepatocytes, leading to apoptosis or necrosis of hepatocytes and eventually to chronic cholestatic liver disease; in certain cholestatic disorders there is also leakage of bile acids into the peribiliary space, causing portal inflammation and fibrosis.
When extracellular pH was experimentally reduced from 7.4 to 6.4, uptake of GCDCA more than tripled, and apoptosis-associated caspase levels increased approximately 10- and 30-fold when incubated with 0.5 mM CDCA or 1 mM GCDCA respectively. This pH-dependent toxicity is relevant to understanding pathological states where local tissue acidosis may augment GCDCA-mediated cell death.
Cholestasis is characterized by accumulation of bile acids and inflammation, causing hepatocellular damage; liver damage markers are highest in acute cholestasis and drop when this condition becomes chronic, indicating that hepatocytes adapt toward the hostile environment — a process that may be explained by a hormetic response in hepatocytes that limits cell death during cholestasis. In experimental work, preconditioning with the pro-apoptotic bile acids GCDCA, taurocholic acid, or the protective bile acids (tauro)ursodeoxycholic acid reduced GCDCA-induced caspase-3/7 activity in HepG2.rNtcp cells.
In cases of primary biliary cholangitis and primary sclerosing cholangitis, bile acid accumulation enhances necrosis and apoptosis of hepatocytes through mitochondrial damage, membrane disruption, and reactive oxygen species (ROS) production.
Hepatocellular Carcinoma (HCC)
Patients with advanced hepatocellular carcinoma (HCC) often develop cholestasis and exhibit poor clinical outcomes; current evidence suggests that dysregulated bile acid metabolism may contribute to HCC progression, and among the bile acids, GCDCA is a key component of cholestasis. Elevated serum levels of GCDCA and GCA were found in patients with HCC, compared to healthy controls, concomitant with a reduction of CDCA. Glycochenodeoxycholic acid has been suggested to be an important indicator for HCC diagnosis and disease prognosis.
An increased risk of developing HCC in cirrhotic patients with elevated total bile acids has been reported; after adjustment for potential confounders, the taurochenodeoxycholic acid/glycochenodeoxycholic acid (TCDCA/GCDCA) and taurodeoxycholic acid/glycodeoxycholic acid (TDCA/GDCA) ratios were both associated with a higher risk of developing HCC four years later; conversely, a decrease in the TCA/CDCA ratio was associated with a reduction in the risk of HCC.
Mechanistically, GCDCA induces stemness and chemoresistance via activating the STAT3 signaling pathway in hepatocellular carcinoma cells. Under pathological conditions, hepatic progenitor cells (HPCs) transform into fibroblasts or tumor-initiating cells, directly promoting liver fibrosis and HCC development; research has aimed to investigate the regulatory role of GCDCA in the activation and differentiation of HPCs to elucidate its potential mechanisms in hepatocarcinogenesis.
Colorectal Cancer
Positive associations have been observed between prediagnostic plasma levels of seven different conjugated bile acid metabolites, including glycochenodeoxycholic acid, and colon cancer risk; these findings support experimental data suggesting that a high bile acid load promotes colon cancer. In a nested case-control study within the European Prospective Investigation into Cancer and Nutrition cohort, pre-diagnostic plasma levels of conjugated bile acid metabolites, including the primary bile acids GCA, TCA, GCDCA, taurochenodeoxycholic acid (TCDCA), and glycohyocholic acid as well as the secondary bile acids GDCA and taurodeoxycholic acid (TDCA), were found to be positively correlated with risk of colon cancer. This epidemiological signal represents an observational association and does not establish causation.
Gut Microbiome and Enterohepatic Axis
Primary bile acids such as unconjugated CA, its taurine and glycine conjugates, and GCDCA were enriched in dysbiotic samples from Crohn's disease (CD) patients, whereas secondary bile acids such as LCA and DCA were obviously reduced, implying that secondary bile acid-producing bacteria are depleted in IBD-related dysbiosis. Primary bile acids are biotransformed by the gut microbiota through reactions including deconjugation catalyzed by bile salt hydrolases (BSH), epimerization to change the orientation of hydroxyl groups on the steroid nucleus, and 7-dehydroxylation.
Immune System and Antiviral Activity
Elderly individuals infected with SARS-CoV-2 are at higher risk of developing cytokine storms; in a study investigating primary bile acid metabolism in elderly patients with severe COVID-19 using untargeted metabolomics (n = 31) followed by targeted metabolomics comparing patients with disease progression (n = 16) to those without (n = 48), significant reductions in CDCA and GCDCA levels were identified in severe cases, with GCDCA levels at admission correlating strongly with peak inflammatory markers. In vitro, CDCA, GCDCA, and their receptors FXR and TGR5 effectively inhibited the inflammatory response induced by SARS-CoV-2; the NOD-like receptor pathway, activated by SARS-CoV-2, may modulate inflammatory cytokines under treatment with CDCA, GCDCA, and TGR5. CDCA and GCDCA levels at admission predicted disease progression, suggesting their potential as biomarkers for severe COVID-19 in the elderly and highlighting their regulatory role in inflammation.
Oncology Immunotherapy Context
In non-small cell lung cancer (NSCLC) patients on immune checkpoint inhibitors (ICIs), elevated plasma taurolithocholic acid (TLCA) and glycochenodeoxycholic acid (GCDCA) correlated with improved outcomes. This observation is preliminary and requires prospective validation before clinical implications can be drawn.
6. Scientific Evidence by Area of Use
6.1 Cholestasis and Liver Disease
The hepatotoxic role of accumulated GCDCA in cholestasis has been established principally in in vitro and animal models. Early studies into the mechanisms of cholestatic liver injury strongly implicated bile acid-induced apoptosis as the major cause of hepatocellular injury; more recent work has focused on both the role of bile acids in cell signaling and the role of sterile inflammation in the pathophysiology. Endogenous Mfn2 expression is significantly reduced in extrahepatic cholestatic patients; GCDCA stimulation decreases Mfn2 expression in L02 cells in a manner similar to the decreased expression detected in patients with extrahepatic cholestasis, indicating that the liver changes seen in patients are a genuine reflection of the changes that occurred in the L02 cells.
Evidence strength: The mechanistic evidence is strong at the preclinical level (in vitro, rodent models, and patient tissue samples), but direct interventional clinical evidence treating cholestasis by manipulating GCDCA levels is lacking. GCDCA serves primarily as a pathological marker and mechanistic probe rather than a therapeutic agent in this context.
6.2 HCC Biomarker Research
Several studies have evaluated serum and occasionally urine bile acid profiles for early detection of HCC; elevated serum levels of GCDCA and GCA were found in patients with HCC compared to healthy controls, concomitant with a reduction of CDCA. Serum metabolomic profiling has been presented as a promising non-invasive approach for the diagnosis of intrahepatic cholangiocarcinoma (iCCA), HCC, and primary sclerosing cholangitis (PSC); the analysis of low-molecular-weight metabolites by high-throughput techniques is a strategy for identifying biomarkers.
The analysis of levels of lipids and amino acids in the serum of patients with iCCA, HCC, and PSC and healthy individuals (n = 20 per group) showed differential profiles; several metabolites presented high diagnostic value for iCCA versus control, HCC versus control, and PSC versus control, with areas under the receiver operating characteristic curve (AUC) greater than those found in serum for the nonspecific tumor markers CA 19-9 and alpha-fetoprotein (AFP).
Evidence strength: Metabolomic studies linking GCDCA elevation to HCC are observational and generally small in sample size (n = 20 per group in key studies). GCDCA is part of a broader bile acid signature rather than a standalone biomarker, and findings remain to be validated in large prospective cohorts.
6.3 Colon Cancer Risk
As noted above, the association between elevated circulating GCDCA and colon cancer risk was observed in the EPIC (European Prospective Investigation into Cancer and Nutrition) nested case-control study. Pre-diagnostic plasma levels of conjugated bile acid metabolites, including GCDCA, were found to be positively correlated with risk of colon cancer. This association is epidemiological; no clinical trials testing modulation of GCDCA as an intervention for colorectal cancer prevention have been identified.
Evidence strength: Observational/epidemiological evidence only. The mechanistic plausibility is supported by in vitro data on bile acid-induced DNA damage and proliferation, but causal direction is uncertain.
6.4 COVID-19 Inflammation
In a study investigating primary bile acid metabolism in elderly COVID-19 patients using untargeted metabolomics (n = 31) followed by targeted metabolomics (n = 64 total), significant reductions in CDCA and GCDCA levels were identified in severe cases, with GCDCA levels at admission correlating strongly with peak inflammatory markers. The in vitro component of this same study demonstrated anti-inflammatory properties of GCDCA, but no clinical trials using exogenous GCDCA supplementation for COVID-19 have been reported.
Evidence strength: A single observational human study combined with cell-based mechanistic data. Highly preliminary; no interventional trials.
6.5 Drug-Drug Interaction Biomarker Research
GCDCA-3G (glycochenodeoxycholate 3-O-glucuronide) is a highly sensitive and specific OATP1B1 biomarker in humans; GCDCA-3G and GDCA-3G are circulating OATP substrates and promising candidates as endogenous biomarkers for OATP-mediated drug-drug interaction (DDI) risk assessment. The sensitivity (98–99%) and specificity (100%) of GCDCA-3G as an OATP1B1 biomarker peaked at a cutoff value of 180 ng/mL for men and 90 ng/mL for women. This is a rapidly developing area in clinical pharmacology, with GCDCA conjugates serving as non-invasive markers for hepatic transporter function rather than as therapeutic entities.
Similarly, changes in GCDCA-sulfate (GCDCA-S) plasma AUC after the administration of OATP1B3 inhibitors were more pronounced than those of creatinine-based probes, supporting its ability to detect weak DDIs even with a smaller sample size; these findings highlight the utility of monitoring GCDCA-S plasma AUC as a Tier 2 biomarker alongside CP-I plasma AUC to delineate between OATP1B1 and OATP1B3-mediated DDIs.
Evidence strength: Reasonably strong for the use of GCDCA conjugates as pharmacokinetic biomarkers; supported by multiple controlled human and in vitro studies with defined sensitivity/specificity metrics.
7. Dosage Forms and Reported Dosages
GCDCA is not available as a standard dietary supplement or approved pharmaceutical agent in isolated form. Its appearance in the research literature is predominantly as an endogenous analyte, a cell-culture reagent, or a reference standard. The following dosages are those specifically reported in experimental or research contexts:
- Incubation of primary rat hepatocytes with 50 μmol/L GCDCA induced morphological features of apoptosis including DNA fragmentation, chromatin condensation, and cellular blebbing.
- In a hormesis study, HepG2.rNtcp cells were preconditioned with sub-apoptotic concentrations (0.1–50 μM) of various bile acids, followed by a challenge with GCDCA at 200 μM for 4 hours.
- Apoptosis-associated caspase levels increased approximately 30-fold when cells were incubated with 1 mM GCDCA.
- In the COVID-19 study, SARS-CoV-2-stimulated THP-1 cells were treated with 10 μM or 20 μM GCDCA for 24 hours.
No established human supplemental or therapeutic dose has been defined for GCDCA in isolation. Its parent compound, chenodeoxycholic acid (CDCA), is approved as a pharmaceutical (e.g., for cerebrotendinous xanthomatosis) but this is distinct from GCDCA itself.
8. Safety Considerations and Drug Interactions
Intrinsic Hepatotoxicity
GCDCA is characterized as a relatively toxic bile salt generated in the liver from chenodeoxycholic acid and glycine. It is a pro-apoptotic bile acid that directly causes apoptosis in vitro in hepatocytes by ligand-independent activation of Fas and probably TRAIL receptor 2/DR5. The cytotoxic threshold in rat hepatocyte models was demonstrated at concentrations from 50 μmol/L upward, with pronounced necrotic effects at 1 mmol/L; advances in modern analytical methodology have allowed for more accurate measuring of bile acid concentrations in serum, liver, and bile, and interestingly, toxic bile acid levels in vivo appear to be far lower than previously hypothesized.
Cholestasis as Pathological Elevation Context
A favored hypothesis is that accumulation of toxic bile acids leads to hepatocyte apoptosis, exacerbating inflammation and liver injury; glycochenodeoxycholic acid (GCDCA), a bile acid, can induce hepatocyte apoptosis in mouse and rat models. When normal enterohepatic circulation is disrupted — as in biliary obstruction, drug-induced cholestasis, or cholestatic liver diseases — GCDCA accumulates to supraphysiological levels in hepatocytes, driving liver damage.
Drug-Drug Interaction Relevance (OATP1B Transporters)
Two bile acid glucuronides, glycodeoxycholate 3-O-glucuronide (GDCA-3G) and glycochenodeoxycholate 3-O-glucuronide (GCDCA-3G), have been identified as OATP1B1 substrates and highly sensitive and specific endogenous biomarkers of OATP1B1 phenotype; GDCA-3G and GCDCA-3G had 6-fold higher OATP1B1-mediated hepatic uptake compared with OATP1B3 and OATP2B1. The genotype–phenotype relationship has demonstrated in adults approximately 6-fold and 9-fold increases in systemic exposure of GDCA-3G and GCDCA-3G, respectively, in those with SLCO1B1 c.521CC genotype relative to SLCO1B1 c.521TT genotype. These findings indicate that drugs inhibiting OATP1B1 (such as certain statins, cyclosporine, rifampicin) can elevate circulating GCDCA conjugates, potentially altering bile acid homeostasis.
Interaction with Protective Bile Acids
Experimental data show that the hepatotoxic effects of GCDCA can be partially modulated by cytoprotective bile acids. Preconditioning with pro-apoptotic bile acids GCDCA, taurocholic acid, or protective bile acids (tauro)ursodeoxycholic acid reduced GCDCA-induced caspase-3/7 activity in HepG2.rNtcp cells, while bile acid preconditioning did not induce significant levels of necrosis in GCDCA-challenged cells. This is consistent with the known cytoprotective effects of ursodeoxycholic acid (UDCA/ursodiol) in clinical cholestatic disease practice.
Potential Role in HCC Promotion
Research indicates that GCDCA induces the differentiation of hepatic progenitor cells (HPCs) into PDGFRA+α-SMA+ cancer-associated fibroblasts (CAFs) by activating the S1PR2 receptor. This mechanism connects chronically elevated GCDCA — as seen in cholestatic liver disease — to a pro-tumorigenic microenvironment. This evidence is currently preclinical and mechanistic in nature.
Absence of Safety Data for Supplemental Use
No formal safety pharmacology studies, toxicity trials, or regulatory assessments of supplemental or exogenous GCDCA in humans have been identified in the peer-reviewed literature. GCDCA is an endogenous metabolite whose concentrations are tightly regulated under normal physiological conditions; its designation as a "dietary supplement ingredient" in commercial contexts is not supported by established monographs from agencies such as the NIH Office of Dietary Supplements, EFSA, EMA, or WHO. The body of evidence consistently frames GCDCA as a molecule whose excess is pathological, and no clinical evidence for benefit of exogenous supplementation has been established.
References
Go back